Oxidative Stress Is Differentially Present in Multiple Sclerosis Courses, Early Evident, and Unrelated to Treatment

Table 4

Oxidative stress markers’ distributions in MS patients according to treatment.

MS	No therapy; (𝑛=53)	IFNB/GA; (𝑛=27)	Other therapies; (𝑛=7)	HC; (𝑛=77)	𝑃^a	𝑃^b	𝑃^t
Q10	536.04±286.19	398.9±189.48	452.35±91.1	616.13±234.19	0.072	0.103	0.001
MDA	7.47±3.57	7.87±2.92	7.58±1.85	07.10±02.46	0.879	0.460	0.30
Glu tot	351.37±109.63	386.38±127.65	453.81±149.17	360.43±99.65	0.063	0.113	0.55
GSH	299.93±119.14	322.22±120.88	413.09±151.01	309.21±102.28	0.056	0.102	0.66
GSSG	54.98±26.59	64.16±28.74	47.28±24.81	51.21±33.29	0.247	0.213	0.26
PAO	961.8±174.98	982.73±149.55	960.0±168.77	1018.25±180.38	0.865	0.929	0.06
Anti-oxLDL	32.93±19.08	37.22±19.77	32.00±22.92	28.08±15.67	0.631	0.517	0.04
ROS	313.85±102.91	317.12±76.64	320.87±94.09	315.31±77.4	0.977	0.940	0.99

No therapy: patients not under DMDs. IFNB/GA: patients using IFNBeta or glatiramer acetate. Other therapies: patients under other treatments (4 on natalizumab, 2 on azathioprine, and 1 on low dose naltrexone) HC: healthy controls. Data are expressed as mean ± SD. Using both parametric (𝑃^a = ANOVA) and nonparametric (𝑃^b) tests, no statistical significant differences were found according to treatment. 𝑃^t shows statistically significant differences between all MS patients and HC.